← boardnext 2027-03-30
GLMD
Galmed Pharmaceuticals Ltddistress 4/10 · elevated risk$0.51-3%today-78% from 52w high
Lead: Healthy
Revenue
pre-revenue
Liquidity
$12M
Runway
1.8 yrs
Shares 1y
0%
Price & events
-40.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.7%
1D
-1.8%
1W
-10.5%
1M
-25.0%
3M
-40.8%
6M
-71.5%
1Y
-87.4%
2Y
-99.9%
5Y
-99.9%
All
Overview
- Market Cap
- $3.32M
- Volume
- 327.50K
- 52 Week Range
- $0.47 – $2.33
- Total Shares
- 6.58M
- Float Shares
- 6.39M
- Short %
- 0.99%
- % Held by Insiders
- 3.30%
- % Held by Institutions
- 1.92%
- RVOL
- 0.50x
- Beta
- 0.74
Pipeline stages · 2 programs
GAL-101
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Aramchol
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-03-30 Estimated 50% readout ~2027-05-14 | Phase 2 | GAL-101 | Geographic Atrophy of the Macula | — | recruiting |
| 2026-04-15 | Phase 1 | Aramchol | Healthy | 32 | recruiting |
| 2025-06-15 | Phase 1 | Aramchol meglumine, Aramchol free acid | Healthy | 16 | completed |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-04-04Maxim GroupBuy → Hold
Competitors — Healthy
- MRKMerck & Co., Inc.$318.8B · D3
- PFEPFIZER INC$142.2B · D3
- SNYSanofi$52.5B · D1
- KYMRKymera Therapeutics, Inc.$9.1B · D5
- SYRESpyre Therapeutics, Inc.$8.5B · D6
- EWTXEdgewise Therapeutics, Inc.$4.1B · D4
- IMNMImmunome Inc.$2.5B · D3
- AVIRAtea Pharmaceuticals, Inc.$379M · D4
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- APGEApogee Therapeutics, Inc.— · D2
Recent news
- 2026-07-23GLMD Q2'26 Earnings: EPS estimate is (0.39) USD - TradingView
- 2026-07-22Galmed Pharmaceuticals Sets August 26, 2026 Annual Meeting to Approve Governance and Structural Changes - TipRanks
- 2026-07-22Galmed Pharmaceuticals (GLMD) sets 2026 AGM on name change and pay - Stock Titan
- 2026-07-18Galmed Accelerates Heart Failure Innovation with Aramchol - t.co
- 2026-07-16Galmed develops heart-targeted formulation of Aramchol drug By Investing.com - Investing.com Nigeria
- 2026-07-16Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD) - Yahoo Finance
- 2026-07-16Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) tests heart-targeted Aramchol LNPs - Stock Titan
- 2026-07-08Galmed (NASDAQ: GLMD) posts Q1 loss and closes Colospan acquisition - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.